Background Image Background Image

Our Strategy

We're fighting to eliminate out-of-pocket costs for patients, extend insurance to everyone in America, and ensure that all drugs go generic without undue delay.

Patients aren't getting proper treatment. Everybody needs to know.

Under the leadership of our Executive Editor, Lynda Gorov, our team of journalists is telling the stories of patients left behind by America's healthcare system. We also draw attention to the problem of drugs that fail to go generic on time, costing America more and eliminating the incentive that drives the industry to innovate.

Explore More

Help today's patients access proper treatments while advocating for reforms to the whole system.

If you or someone you know is struggling to afford a treatment that your doctor says is right for you, we may be able to help:

Here's Our Approach:

  • icon
    View Key Resources

    Charities, drug company patient assistance programs, and HarborPath.

  • icon
    Get Media Attention

    If you are battling your insurance company, our journalists may be interested in your story and might be able to draw attention to your case.

    Share your story
  • icon
    Fight with your Plan

    There are strategic tactics that will help you get past an initial “no.” We’ll show you how.

    Learn More
  • icon
    Harbor Path

    HarborPath is a non-profit that offers free medications to uninsured people without other options. NPLB has funded and is working with HarborPath to expand its collection of medicines and help a wider variety of patients.

    Learn More

Lower out-of-pocket costs. Extend insurance to everyone. Ensure all drugs go generic.

Name-brand drugs are like rent: their costs keep rising. Generics are the equivalent of a mortgage: fixed costs and stability. All drugs need to go generic without undue delay once their patents expire so society can own what we've invested in.

Here's Our Approach:

  • icon
    Engage with Lawmakers & Healthcare Staffers

    We're working to win over members of Congress so that they choose our proposals--which actually help patients--over others they hear.

    See our Proposal to Lawmakers
  • icon
    Quantify the impact of our proposal

    We work with economists, data providers, and experts to answer questions such as "How much value does America get when drugs go generic?"

    Explore more

We're bringing together representatives from across healthcare to refine our proposal and secure support.

Here's Our Approach:

  • icon
    Physicians (and patients) may wonder whether out-of-pocket costs will be replaced with more onerous prior authorizations.
  • icon
    Insurers and Employers need to know what impact our reforms will have on premiums.
  • icon
    PBMs need to be able to stoke price competition among drug companies with similar drugs.
  • icon
    Drug companies need to know that there will still be incentives for new drugs if old ones are contractually genericized.
  • icon
    Generics manufacturers will want to know that there’s still a role for them if drugs increasingly go generic by contract.